Phase 1 Trial of Ebola Vaccine in Mali

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

April 20, 2016

Study Completion Date

April 20, 2016

Conditions
Ebola Virus DiseaseHemorrhagic Fever
Interventions
BIOLOGICAL

Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z

IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):

BIOLOGICAL

Booster-MVA-BN® Filo or saline placebo

IM injection of Booster-MVA-BN® Filo or saline placebo

Trial Locations (1)

Unknown

Center for Vaccine Development, Mali, Bamako

Sponsors
All Listed Sponsors
collaborator

Wellcome Trust

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Leidos Biomedical Research, Inc.

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT02267109 - Phase 1 Trial of Ebola Vaccine in Mali | Biotech Hunter | Biotech Hunter